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Summary
To assess the potential of Drosophila to analyze clini-
cally graded aspects of human disease, we developed
a transgenic fly model to characterize Presenilin (PS)
gene mutations that cause early-onset familial Alz-
heimer’s disease (FAD). FAD exhibits a wide range in
severity defined by ages of onset from 24 to 65 years
[1]. PS FAD mutants have been analyzed in mamma-
lian cell culture, but conflicting data emerged concern-
ing correlations between age of onset and PS bio-
chemical activity [2–4]. Choosing from over 130 FAD
mutations in Presenilin-1, we introduced 14 corre-
sponding mutations at conserved residues in Dro-
sophila Presenilin (Psn) and assessed their biological
activity in transgenic flies by using genetic, molecular,
and statistical methods. Psn FAD mutant activities
were tightly linked to their age-of-onset values, provid-
ing evidence that disease severity in humans primarily
reflects differences in PS mutant lesions rather than
contributions from unlinked genetic or environmental
modifiers. Our study establishes a precedent for using
transgenic Drosophila to study clinical heterogeneity
in human disease.
Results and Discussion
Presenilin is an evolutionarily conserved polytopic
membrane protein that is part of the multisubunit g-sec-
retase complex responsible for intramembranous cleav-
age of several transmembrane proteins, including APP,
Notch, Delta, DCC, ErbB4, N-Cadherin, and E-Cadherin
[5]. Familial Alzheimer’s disease (FAD) mutations in Pre-
senilin-1 (PS1) and PS2 alter proteolytic processing of
APP to generate more toxic Ab42 peptides that acceler-
ate amyloid plaque formation in brain tissues [6]. PS mu-
tations also contribute to neurodegeneration and
*Correspondence: fortini@ncifcrf.govcognitive decline through amyloid-independent mecha-
nisms [7], involving altered regulation of receptor signal-
ing and intracellular kinase pathways [7–10].
The Drosophila APP ortholog, APPL, lacks homology
to APP within the Ab peptide region, and loss of APPL
produces subtle behavioral deficits that are difficult to
measure quantitatively [11]. A more suitable substrate
to monitor Presenilin (Psn) FAD mutant activity in Dro-
sophila is the Notch receptor, the most extensively char-
acterized fly g-secretase substrate. Psn is required
throughout Drosophila development for Notch signal-
ing, and a wide variety of Notch-related phenotypes ex-
ist that range from severe embryonic lethality to specific
defects in adult tissues. This phenotypic range is ame-
nable to characterizing variable degrees of function
among different Psn FAD mutants. In addition, genetic
and molecular reagents are available to characterize
Notch biochemical cleavage and subsequent target-
gene activation in Drosophila.
Previous studies have successfully used transgenic
mice and C. elegans to assess the genetic properties
of human PS FAD mutants [12–15], and one study sug-
gested a potential difference between two FAD variants
[14]. However, quantitative comparison between FAD
mutants was not practical because of heterologous ex-
pression methods and difficulties controlling transgene
copy numbers. Two studies in mammalian cell culture
showed little or no relationship between average ages
of onset and Ab42 secretion levels [3, 4], contrary to
one study reporting a strong correlation [2].
We assessed PS FAD mutant function in Drosophila
by expressing 14 FAD-linked mutant psn transgenes in
animals lacking endogenous psn function. The muta-
tions were selected on the basis of the following criteria:
(1) they span the entire protein (Figure 1A), (2) relatively
large numbers of families and affected individuals have
been identified for most mutations (Figure 1B), and (3)
their ages of onset range from 24 to 65 years, or are pos-
sibly asymptomatic (E318G and F175S; Figure 1B) [16–
19]. Thirteen of the mutations affect residues that are
conserved in fly Psn, and the remaining one alters a con-
servatively substituted residue (Figure 1A). To achieve
physiological expression of the transgenes, we defined
a 1.5 kb promoter, termedPEPC (Presenilin endogenous
promoter cassette), of the endogenous psn gene. At the
larval-pupal transition, loss of psn function causes
highly uniform lethality that is fully rescued by a wild-
type PEPC-psn transgene but not by wild-type human
PS1 or PS2 transgenes driven by PEPC (data not
shown). To circumvent this technical problem with hu-
man PS transgenes, we engineered each FAD mutation
into the fly psn gene.
Examining transgenic lines expressingPEPC-psnFAD
mutants in a psn null genetic background, we defined
eight distinct phenotypic categories that represent
a graded series in order of increasing rescue ability, as
follows: (1) prepupal lethal, (2) late prepupal lethal, (3) pu-
pal lethal, (4) pharate lethal, (5) severe neurogenic/adult
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1027Figure 1. FAD-Associated Mutants in PS1 Selected for Analysis in Transgenic Drosophila
(A) Diagram of human PS1 indicating the 14 FAD-associated missense mutations that were engineered into Drosophila Psn. Solid, shaded, and
open circles represent identical, similar, and nonconserved amino acids, respectively, between human and Drosophila Presenilins. Red and
green circle borders indicate sites of pathogenic and nonpathogenic substitutions, respectively.
(B) FAD mutant average ages of onset (AAO), the number of affected families (# of Fam), and total number of affected patients (Pat). AAO values
for the asymptomatic variants E318G and F175S are given as ‘‘no phenotype’’ (No Ph.) [19].lethal, (6) moderate neurogenic/adult viable, (7) weak
neurogenic/adult viable, and (8) morphologically normal
(Figure 2). Quantitative analysis of survival rates, inci-
dence of dorsoscutellar bristle duplications, wing notch-
ing, wing vein defects, and other morphological features
was performed to assign each transgenic line to the ap-
propriate rescue category (see Table S1 in the Supple-
mental Data online for details of quantitative scoring).
The phenotypic categories are consistent with an or-
dered series attributable to progressive increases in
Psn-dependent Notch activation, but it was important
to verify that they do not instead represent the effects
of Psn on other substrates. In the canonical Notch path-
way, ligand binding to the Notch receptor leads to ecto-
domain removal and subsequent g-secretase-mediated
intramembranous cleavage of Notch [20]. The liberated
intracellular domain, termed NICD, translocates to the
nucleus and participates directly in transcriptional regu-
lation of target genes, including the Enhancer of split m7
(E(spl)m7) gene in Drosophila [21]. Activation of Notch
signaling within proneural cell clusters destined to give
rise to adult sensory organs results in restricted expres-
sion of the proneural marker scabrous (sca) [22]. Visual-
ization of sca expression in the larval imaginal wing disc
with a sca-lacZ transgene provides evidence for a pro-
gressive range of Notch signaling with different PEPC-
psn transgenes (Figures 2E–2H).
Biochemical evidence for progressively increasing
Psn function was obtained by immunoblot analysis of
Notch cleavage products across the spectrum of
PEPC-psn FAD phenotypes (Figure 3). Representative
PEPC-FAD transgenic lines of the different categoriesexhibit partial-to-complete failure in g-secretase-medi-
ated NICD production. Interestingly, although trans-
genic lines belonging to categories 2–4 exhibit signifi-
cant levels of biological rescue activity, they do not
produce levels of NICD detectable by immunoblot anal-
ysis. These results demonstrate that genetic assays
such as ours are valuable for studying low-level or tis-
sue-specific aspects of g-secretase substrate cleavage
that might not be amenable to biochemical analysis.
To determine whether the PEPC-psn FAD phenotypic
series is similarly correlated with Notch target-gene ac-
tivation, we used semiquantitative RT-PCR to monitor
activation of the E(spl)m7 gene (Figure 4). Normalizing
transcriptional activation to two control genes, we ob-
served a progressive increase in E(spl)m7 transcript
levels across categories 1–8, confirming that they repre-
sent graded increases in g-secretase-dependent Notch
activation. To verify this relationship, we utilized a tem-
perature-sensitive Notch allele termed Nts1. Incremental
levels of Notch activity obtained by raising Nts1 flies at
different temperatures produced phenotypes matching
those seen in the Psn FAD mutant series, but were inde-
pendent of manipulations involving endogenous or
transgenic Psn. Levels of E(spl)m7 transcriptional acti-
vation seen in these Nts1 phenotypic classes resembled
closely those observed in the corresponding PEPC-psn
FAD classes, confirming the progressive increase in
Notch target-gene activation across this phenotypic
spectrum (Figure 4). Taken together, these results vali-
date the use of our phenotypic criteria to characterize
varying degrees of PEPC-psn FAD transgene activity to-
ward the endogenous g-secretase substrate Notch.
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1028Figure 2. Representative Phenotypes Used to Assess Functional Rescue Activity of Psn FAD Mutants in Transgenic Drosophila
(A–H) Adult-lethal categories 1–4 exhibit progressively later lethality and increased morphological rescue during pupal stages ([A–D]; red arrow-
head, rudimentary head structure; black arrowhead, early leg structures in [C]) and progressively more normal proneural cluster patterning as
visualized by sca-lacZ labeling [24, 25] (E–H).
(I–P) Increasingly normal thoracic bristle patterning (I–L) and more complete wing development (M and N) across adult-viable categories 5–8 as
indicated at top (red arrowhead in [K], duplicated dorsoscutellar macrochaete; red arrowhead in [J], patch of missing microchaetae; blue arrow-
head in [N], mild wing notching; black arrowheads in [N] and [O], wing vein deltas; and red arrowhead in [N], wing vein gap).
(Q–T) Small, roughened eye phenotype of a category 5 adult (Q) containing supernumerary photoreceptor cells ([R], red arrowhead) as compared
to a fully rescued category 8 wild-type Psn transgenic adult retina (S and T). For phenotypic classification, single-copy PEPC-psn transgenes
were introduced into flies lacking endogenous psn function and scored with several quantitative measures, as described in Table S1. Anterior
is at top ([A–D] and [I–L]), right (E–H), and left ([M–Q] and [S]).A limitation of transgenic analysis in Drosophila is that
the transgenes are inserted at essentially random geno-
mic locations, leading to variations in expression as a re-
sult of local position effects at different sites. These ef-
fects are a confounding factor in our comparisons of
relative degrees of rescue function, which reflects prop-
erties of the primary lesion in each Psn mutant protein as
well as the expression level of each transgenic insertion.
We therefore generated from four to 16 independentinsertions for each transgene, and each insertion was
scored with multiple quantitative morphological criteria
and assigned to the appropriate phenotypic category
(see above and Table S1). The resulting data for all 162
transgenic lines, representing 14 PEPC-psn FAD mu-
tants and one wild-type Psn control construct, are
graphically presented in Figure 5A. Visual inspection
suggests a positive overall trend between increasing
age of onset in human FAD pedigrees and increasingFigure 3. Levels of Notch Intramembrane
Proteolysis in Psn FAD Mutant Transgenic
Flies
Notch-activation results in ectodomain re-
moval and generation of membrane-an-
chored C-terminal NEXT (upper band), which
is cleaved intramembranously by g-secre-
tase to produce NICD (lower band; arrow at
right). Nontransgenic psn null mutant larvae
fail to produce detectable NICD from NEXT
(leftmost lane). Transgenic lines bearing dif-
ferent Psn FAD transgenes in this psn null
background exhibit increasing NICD levels
that correlate with their degree of morpholog-
ical rescue, as noted above each lane (No tg
denotes no transgene; wt denotes wild-type).
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1029Figure 4. Psn FAD Transgenic Flies Exhibit a Graded Range of E(spl)m7 Transcriptional Activation Correlated to Their Notch Signaling
Phenotypes
Transcriptional activation of the Notch target gene E(spl)m7 (y axis) was monitored by RT-PCR across a representative sampling of Psn FAD
transgenic lines covering the eight morphological categories (x axis). E(spl)m7 transcript levels were normalized to levels of Notch mRNA, be-
cause Notch signaling is sensitive to receptor dosage [26] and Notch transcription might thus be susceptible to perturbations in Psn activity. We
confirmed RT-PCR results of E(spl)m7 normalized toNotch (blue symbols) with an independent RT-PCR using ribosomal-protein geneRp49 (red
symbols) for normalization. RT-PCR ratios for transgenic lines bearing a single-copy PEPC-psn FAD construct in a psn null background are in-
dicated as circles; control genotypes are as follows: wild-type (red and blue diamonds), Nts1 flies raised at different temperatures (yellow
squares), psn homozygote null (red and blue triangles), and psn heterozygotes (green diamond). Error bars represent 6 standard error of the
mean.biological activity for these FAD mutants in transgenic
Drosophila.
To investigate this potential trend, we applied a num-
ber of statistical tests to the transgenic scoring data. We
used exclusively nonparametric tests that treat the data
only as ordinally ranked categories. This conservative
approach was used because age-of-onset figures are
derived from relatively small human sample sizes, and
we cannot affix quantitative values to the eight pheno-
typic rescue categories, although we are confident of
their progressive ordinal ranking. The Jonckheere-Terp-
stra test [23] for ordered alternatives is a nonparametric
test that fits these assumptions. For this analysis, the
very-late-onset/probable asymptomatic mutants F175S
and E318G were placed in a single group ordered prior
to the wild-type Psn transgene. Using this test, we find
a highly significant correlation between the age-of-onset
ranking of the FAD mutants and the relative biological
activities of the corresponding Psn mutant transgenes
(p < 0.0001; J-T statistic = 6.9). We also analyzed the
data with Spearman’s rho [23], a nonparametric testfor correlation between two variables without the as-
sumption of a linear relationship, which similarly demon-
strates a highly significant correlation between age-of-
onset values and biological activities in Drosophila (p <
0.0001; correlation = +0.531).
The above tests demonstrate an overall correlation
across the dataset as a whole, but Figure 5A indicates
that the correlation is not smooth. Most FAD mutants ap-
pear to cluster in groups separated by discontinuities,
with a few mutants that are noticeably different from
nearby mutants. To investigate these features, we per-
formed pairwise rank-sum comparisons between all in-
dividual Psn FAD mutants with the Wilcoxon-Mann-
Whitney test, a nonparametric method for analyzing
the overlap between distributions of two independent
groups [23]. We found that mutants having similar ages
of onset are, in general, not statistically different from
one another (Figure 5B). Nevertheless, the mutants can
be statistically grouped into three distinct classes:
strong (L166P, L173W, P436Q, V272A, and L235P; Fig-
ures 5C and 5D), intermediate (M146L, M139V, H163R,
Current Biology
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1031E280A, A246E, and G206A; Figure 5E), and weak (A79V,
F175S, and E318G; Figure 5F). Strong mutants differ
most clearly from the weak ones in terms of function (Fig-
ures 5C and 5D), and vice versa (Figure 5F), whereas the
intermediate group shows more modest differences
compared to either of these two flanking groups (Fig-
ure 5E). Pairwise comparisons of aggregated mutant
groups confirmed these classes. The strong mutant
group is significantly different from both the intermediate
and weak groups (p < 0.0001 in both cases). Despite its
age of onset ofw60, the A79V mutant is more similar to
the weak mutants than the intermediate ones, as con-
firmed by pairwise comparisons of aggregated interme-
diate and weak groups with A79V assigned to either the
intermediate (p = 0.0027) or the weak group (p = 0.00049).
Similarly, two mutants, L235P and P436Q, are less
functional in transgenic flies than might be predicted
on the basis of their ages of onset, whereas another mu-
tant, M139V, is somewhat more functional than ex-
pected. Whether these disparities reflect inadequate
age-of-onset data, modifier effects in the corresponding
human pedigrees, or an unknown feature of the fly assay
system is not clear. Finally, the E318G and F175S mu-
tants, proposed to be either very weak pathogenic mu-
tants or functionally normal polymorphisms, are statisti-
cally indistinguishable from the wild-type transgene in
our genetic assay, consistent with the idea that they
are nonpathogenic polymorphisms. Overall, our results
support the assertion that disease severity in early-on-
set Alzheimer’s disease is primarily determined by PS
mutant lesion type as opposed to unlinked genetic or
environmental modifiers, as was also deduced from
a study of Ab secretion levels in PS FAD mutant trans-
fected cells [2].
A few other interesting patterns emerge from these
comparisons. Mutants for which relatively few indepen-
dent lines were obtained, most notably H163R (n = 4), fail
to show significant differences when compared to other
mutant groups (Figures 5C–5F). On the basis of the com-
plete dataset, we estimate that w10 independent lines
of a given mutant are required to obtain statistically use-
ful data. This problem might be circumvented by em-
ploying a ‘‘knock in’’ strategy to precisely replace the en-
dogenous psn gene with FAD variants, an approach that
is not yet reliable in Drosophila. Additionally, one source
of experimental noise is that transgenes occasionally in-
sert into locations where they are poorly expressed or
damaged during insertion, as is evident from a few in-
stances involving the ‘‘asymptomatic’’ F175S andE318G mutant and wild-type transgenes. Normalization
of functional read-outs for each transgene insertion rel-
ative to its mRNA or protein expression level in the ap-
propriate transcript null or protein null psn mutant back-
ground should reduce this noise and lead to further
refinement of the statistical data.
Our findings establish the validity of using transgenic
Drosophila or other heterologous organisms to evaluate
clinically heterogeneous aspects of human diseases
with a clearly defined genetic etiology. Transgenic Dro-
sophila offer several advantages to augment more tradi-
tional clinical assessments as well as transgenic mouse
models. Transgenic flies are relatively inexpensive and
rapid to produce, large numbers of independent lines
can be easily generated, and limitless numbers of prog-
eny for each line can be examined under controlled ge-
netic conditions. These features of our assay might
make it useful for obtaining a rapid estimate of approx-
imate disease severity for new PS1 and PS2 mutations,
especially for those with limited pedigree data, small
numbers of affected individuals, or suspected environ-
mental or genetic confounding factors. Although the
primary goal of this study was to assess an array of ge-
netically diverse FAD mutant variants in a more stan-
dardized genetic background, the transgenic flies we
characterized could be used to study the effects of sus-
pected modifiers or search for new modifiers of PS func-
tion. The transgenic lines could also be combined with
APP-expressing transgenes to investigate more directly
the role of PS FAD mutants in APP cleavage, amyloid-
peptide accumulation, and neurotoxicity in a fly model.
The correlation we observe between the effects of differ-
ent FAD mutations on Drosophila Notch signaling and
human disease onset underscores recent proposals
that in addition to APP processing, more global pertur-
bations in pathways involving other g-secretase sub-
strates should be considered in early-onset Alzheimer’s
disease [7–10]. Finally, our results offer encouragement
that additional transgenic Drosophila models might be
developed to investigate clinical heterogeneity in other
human diseases.
Experimental Procedures
FAD-Linked PEPC-psn Mutant Transgenes
Psn FAD transgenes generated by overlapping PCR were shuttled
into the vector pCaSpeR containing a Drosophila wild-type psn
cDNA backbone driven by the 1.5 kb psn promoter (PEPC), and mis-
sense mutation regions were sequenced. Transgenic animals were
generated by embryo injection, and additional lines were producedFigure 5. Correlation between Presenilin FAD Mutant Age of Onset in Human Pedigrees and Functional Activity in Transgenic Drosophila
(A) Morphological scoring of Psn FAD mutant transgenic lines. Each point represents an individual independent PEPC-psn FAD transgenic line,
with color denoting each FAD mutant amino acid substitution positioned on the x axis according to increasing age of onset in years (error bars
represent6 average deviation of the mean). The y axis represents the assignment of each transgenic line to one of the morphological categories
at left, reflecting increasing transgene function (see Table S1 for quantitative scoring). Equivalent points have been evenly dispersed for clarity
(wt denotes wild-type transgene).
(B) P values for pairwise Wilcoxon-Mann-Whitney tests. Each box shows the p value for one test performed between the corresponding FAD
mutants shown at left and at top. P values <0.001 level are in yellow, those between 0.05 and 0.001 are in blue, and those that do not reach sta-
tistical significance are in white; asterisks indicate significant p values with an unexpectedly negative correlation between age of onset and
relative transgenic activity.
(C–F) Plots of pairwise Wilcoxon-Mann-Whitney p values. Each plot shows the p values for all pairwise comparisons, with the 14 Psn FAD mutants
and wild-type control arranged ordinally by age of onset and color-coded along the x axis, and with the negative log of the p value plotted on the y
axis. Color coding of p values and connecting lines identifies the mutant group being compared to all the other mutants across the plot. For clarity,
pairwise data are shown for Psn FAD mutant subsets in different plots as follows: (C) L166P and L173W; (D) P436Q, V272A, and L235P; (E) M146L,
M139V, H163R, E280A, A246E, and G206A; and (F) A79V, F175S, E318G, and wild-type (F175S and E318G are grouped as ‘‘asymptomatic’’).
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cDNAs rescued psn null animals with no distinguishable difference
(data not shown), so all FAD variant transgenes were made with
the longer splicing variant.
Notch immunoblot analysis
Crosses were performed to generate larvae bearing a single-copy
Psn FAD transgene (PEPC-psnX###Y) in a psnB3 null background,
and third-instar-larval brain-disc complexes were harvested and
lysed in hypotonic buffer as described [24]. Total lysates were son-
icated, and 40 mg of total protein per sample was resolved on a Bio-
Rad Criterion XT 3%–8% Tris-Acetate gel, transferred to nitrocellu-
lose, and probed with mouse anti-Notch 9C6 antibody (1:1000
dilution) recognizing the Notch intracellular domain (University of
Iowa Developmental Studies Hybridoma Bank), followed by HRP-
conjugated goat anti-mouse antibody (1:5000 dilution; Jackson
Immunoresearch).
E(spl)m7 Semiquantitative RT-PCR
Duplex PCR was performed with four concentrations of a 2-fold ti-
tration of first-strand synthesis from third-instar-larval total RNA.
PCR products were visualized by SyberGreen (Molecular Dynamics)
staining and quantitated with Fuji ImageQuant software, and relative
absorbance units were plotted against template concentration.
Slopes best fitting a straight line (R2 R 0.95) were taken as the
rate proportional to transcript levels.E(spl)m7 rates were normalized
to similarly derived values for eitherNotch orRp49, and final normal-
ized data were graphed by setting psn null and wild-type control
values at 0% and 100%, respectively. Data represent at least three
independent PCR reactions with at least two replicated total-RNA
preparations per sample (except ‘‘severe neurogenic/adult lethal’’
Rp49 normalized samples, n = 2). Nts1 animals were grown in contin-
uous culture at five temperature increments between the permissive
(19ºC) and restrictive conditions (31ºC), then harvested for RT-PCR
or allowed to develop for phenotypic scoring. RT-PCR primer se-
quences are given in Table S2.
Supplemental Data
Supplemental Data include two tables and are available with this
article online at: http://www.current-biology.com/cgi/content/full/
16/10/1026/DC1/.
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